Bausch & Lomb IOL deal
This article was originally published in The Gray Sheet
Executive Summary
Eye care giant gains worldwide rights, excluding Japan, to Santen Pharmaceutical's hydrophobic acrylic polymers, which will be used in the development of intraocular lenses. B&L currently markets IOL products including Crystalens, the only FDA-approved accommodating IOL, Akreos and SofPort. The acquisition of Crystalens maker Eyeonics in 2008 marked B&L's entry into the premium IOL market, in which it competes with Alcon and Abbott subsidiary Advanced Medical Optics (1"The Gray Sheet" Jan. 28, 2008, p. 3)